Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. H. Lundbeck A/S
  6. Summary
    LUN   DK0010287234

H. LUNDBECK A/S

(LUN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
191.85(c) 197.15(c) 198.3(c) 196.5(c) 193.55(c) Last
370 299 1 041 054 458 844 641 966 514 673 Volume
-0.39% +2.76% +0.58% -0.91% -1.50% Change
More quotes
Financials
Sales 2021 16 640 M 2 710 M 2 710 M
Net income 2021 1 484 M 242 M 242 M
Net Debt 2021 2 283 M 372 M 372 M
P/E ratio 2021 26,3x
Yield 2021 1,45%
Sales 2022 17 688 M 2 880 M 2 880 M
Net income 2022 2 233 M 364 M 364 M
Net cash position 2022 132 M 21,5 M 21,5 M
P/E ratio 2022 17,5x
Yield 2022 2,16%
Capitalization 38 458 M 6 258 M 6 262 M
EV / Sales 2021 2,45x
EV / Sales 2022 2,17x
Nbr of Employees 5 551
Free-Float 30,7%
More Financials
Company
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as AlzheimerÔÇÖs disease, Bipolar disorder, depression, epilepsy, HuntingtonÔÇÖs disease, ParkinsonÔÇÖs disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression... 
Sector
Pharmaceuticals
Calendar
08/18Earnings Release
More about the company
Ratings of H. Lundbeck A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about H. LUNDBECK A/S
05/31H LUNDBECK A/Sá : Interpretation Of The Term "export" In The Indian Patent Conte..
AQ
05/26H LUNDBECK A/Sá : Transactions with shares and linked securities in H. Lundbeck ..
AQ
05/11H LUNDBECK A/Sá : Lundbeck delivers a solid EBIT of DKK 882 million and Vyepti i..
AQ
05/03H LUNDBECK A/Sá : Lundbeck - New study finds that vortioxetine helps patients wi..
AQ
05/03H LUNDBECK A/Sá : Lundbeck Drug Improves Symptoms in People With Major Depressiv..
MT
05/03H LUNDBECK A/Sá : New study finds that vortioxetine helps patients with MDD and ..
AQ
04/22H LUNDBECK A/Sá : Vortioxetine significantly improves overall functioning in a g..
AQ
04/13H LUNDBECK A/Sá : Lundbeck and Otsuka announce decision to continue phase III cl..
PU
04/13H LUNDBECK A/Sá : Lundbeck, Otsuka to Push Through With Recruitment in Late-Stag..
MT
04/13H LUNDBECK A/Sá : Lundbeck and Otsuka announce decision to continue phase III cl..
AQ
03/24H. LUNDBECK A/S : Ex-dividend day for final dividend
FA
03/23H LUNDBECK A/Sá : Lundbeck held its Annual General Meeting on 23 March 2021 as a..
AQ
03/19Scandion Oncology Appoints New COO
MT
03/17H LUNDBECK A/Sá : Lundbeck appoints Dr. Tarek Samad as Head of Research
AQ
03/12H LUNDBECK A/Sá : Supplement to notice of Annual General Meeting
PU
More news
News in other languages on H. LUNDBECK A/S
05/12MSCI streicht Hochtief-Aktie aus Deutschland-Index
05/11STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
05/06ÜBERBLICK/Anstehende Indexänderungen
04/13H. LUNDBECK A/Sá : coup d'arrêt
03/22ÜBERBLICK/Anstehende Indexänderungen
More news
Analyst Recommendations on H. LUNDBECK A/S
More recommendations
Chart H. LUNDBECK A/S
Duration : Period :
H. Lundbeck A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends H. LUNDBECK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 247,43 DKK
Last Close Price 193,55 DKK
Spread / Highest target 55,0%
Spread / Average Target 27,8%
Spread / Lowest Target -5,45%
EPS Revisions
Managers and Directors
NameTitle
Deborah L. Dunsire President & Chief Executive Officer
Anders G÷tzsche Chief Financial Officer & Executive Vice President
Lars S°ren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
H. LUNDBECK A/S-7.30%6 258
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.72%203 857